Cost-effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: an economic evaluation based on the MifeMiso trial

Author(s) Okeke Ogwulu C.B.; Williams E.V.; Roberts T.E.; Chu J.J.; Devall A.J. et al.
Source BJOG: An International Journal of Obstetrics and Gynaecology; 2021

Objective: To assess the cost-effectiveness of mifepristone and misoprostol (MifeMiso) compared with misoprostol only for the medical management of a missed miscarriage. Design(s): Within-trial economic evaluation and model-based analysis to set the findings in the context of the wider economic evidence for a range of comparators. Incremental costs and outcomes were calculated using nonparametric bootstrapping and reported using cost-effectiveness acceptability curves. Analyses were performed from the perspective of the UK's National Health Service (NHS). Setting(s): Twenty-eight UK NHS early pregnancy units. 

• Available in full text at BJOG : an international journal of obstetrics and gynaecology from Wiley - Blackwell Publishing